TITLE

Authorized generics gaining popularity

AUTHOR(S)
Johnsen, Michael
PUB. DATE
September 2005
SOURCE
Drug Store News;9/26/2005, Vol. 27 Issue 12, p56
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that branded pharmaceutical companies in the U.S. are turning more and more to authorized generics as part of a viable drug life cycle. Percentage share of branded generics in the pharmaceutical market for the year ended in June 2005; Branded companies still battling generics manufacturers in court in an effort to protect their patents.
ACCESSION #
18453119

 

Related Articles

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • Who really is profiting from the branded generics.  // Fort Worth Business Press;11/21/2003, Vol. 16 Issue 45, p36 

    Provides information on branded generic drugs. Description of branded generic; Reasons that the first generic company to enter usually captures most of the available generic profits; Benefits and setbacks of launching a branded generic to a drug company.

  • Czy lek generyczny daje ten sam efekt terapeutyczny Co lek oryginalny? GÅ‚os w dyskusji. Matusiak, ŀukasz; Szepietowski, Jacek; Baran, Eugeniusz // Medical Mycology / Mikologia;2007, Vol. 14 Issue 1, p9 

    The suddenly rising health care expenditures, attributed mainly to the high cost of prescription drugs, have led governments around the world to pay more attention to generics. Generic drugs provide less expensive alternative to brand name drugs due to the elimination of the need to perform...

  • Go Go Generics.  // Pharmaceutical Executive;Dec2009, Vol. 29 Issue 12, p24 

    The article discusses developments in the market for generic drugs since the introduction of the Hatch-Waxman Act in the U.S. in 1984. It mentions that generics comprised 70 percent of prescription drugs in the country which are promoted by health plan providers and pharmacy benefit managers...

  • THE HATCH-WAXMAN ACT AND MARKET EXCLUSIVITY FOR GENERIC DRUG MANUFACTURERS: AN ENTITLEMENT OR AN INCENTIVE? Mehl, Ashlee B. // Chicago-Kent Law Review;2006, Vol. 81 Issue 2, p649 

    One of Congress' central goals in enacting the Hatch-Waxman Act was to expedite and encourage earlier market entry for generic pharmaceutical products. The Act provides that a generic firm may challenge a drug patent during its term by filing paperwork with the FDA that alleges either that its...

  • Top Generic-Drug Firms Go Into Branded. DAVID SAITO-CHUNG // Investors Business Daily;10/7/2014, pB06 

    In the past, it was easy to separate the ethical-drug makers that marketed proprietary medicines and the generics makers that specialized in making copies of such branded medicines.

  • Broad generic substitution leads to "significant" healthcare savings.  // PharmacoEconomics & Outcomes News;8/13/2005, Issue 484, p7 

    Presents a study which estimated the potential savings associated with the substitution of brandname drugs with generic drugs or multisource drugs. Median annual savings per person with broad generic substitution for adults aged below 65 years; Estimated national savings with broad generic...

  • GP prescribing incentives hit by generic substitution.  // GP: General Practitioner;3/6/2009, p9 

    The article discusses the plan that allows generic name substitution by pharmacists over the prescribing incentives of the general practitioner (GP). It notes that under the plans being discussed by the pharmaceutical industry and the Department of Health (DoH), pharmacist could substitute drugs...

  • The adverse effects of brand-name drug prescribing. Flegel, Ken // CMAJ: Canadian Medical Association Journal;3/20/2012, Vol. 184 Issue 5, p616 

    The article focuses on the negative effect of prescribing brand-name drugs. It says that brand-name drug prescription is considered a bad practice for physicians due to its expensive prices and lack of other useful information. It mentions that brand-name drugs are designed to promote and sell...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics